

**Socio-demographic and obstetric variations of *T. gondii* and HIV-1 co-infection among pregnant women in Cameroon**

**ABSTRACT**

**Aims:** This study, aimed to identify the seroprevalence of *T. gondii* and HIV-1 co-infection in pregnant women in the Northwest Region of Cameroon.

**Study design:** This cross-sectional study was conducted among 606 pregnant women attending antenatal clinic in the Northwest region of Cameroon.

**Place and Duration of Study:** This study was carried out at the Bamenda Regional Hospital from May 2017 to December 2017.

**Methodology:** Venous blood samples were collected for the detection of anti-*Toxoplasma* antibodies using rapid test kits while HIV was determine using Alere Determine™ HIV-1/2 test kit and OraQuick HIV 1/2 Rapid Antibody Test kit for confirmation. Data were analyzed using SPSS version 23 statistical package. P-value <0.05 was considered statistically significant.

**Results:** The mean (SD) age was 27.3 (5.3) years. The prevalence of *T. gondii* and HIV-1 was 139 (22.9%) and 70(11.6%) respectively, while that of *T. gondii* and HIV-1 co-infection was 31(5.1%). With the exception of age group and gestational age that was significant (p<0.05) for HIV, socio-demographic and obstetrical characteristics of *T. gondii*, HIV-1 and *T. gondii* and HIV-1 co-infection prevalence did not show any significant differences (p>0.05). **Conclusion:** The high prevalence of *T. gondii* and HIV-1 co-infection seen in this study demonstrates the need for routine antenatal screening for both infections. In addition, data from this study will be useful in designing control and prevention strategies against these diseases. Furthermore, the result will also be used as baseline data for further research on *T. gondii* and HIV-1 co-infection.

**Keywords:** Co-infection Human immunodeficiency virus, Pregnant women, Toxoplasmosis, Cameroon

**1. INTRODUCTION**

Antenatal care (ANC) provides adequate measures against maternal-fetal transmission of several diseases, including toxoplasmosis and HIV [1, 2]. Toxoplasmosis caused by *Toxoplasma gondii* is a neglected zoonotic disease and is asymptomatic [3, 4]. Toxoplasmosis is prevalent worldwide whereby about one third to half of the global population is infected [5-7]. Human infections result from food borne transmission (consumption of water, raw or undercooked meat or unpasteurized milk contaminated with cyst), animal to human transmission (ingestion of oocysts through close contact with infected cats or cat's faeces), mother-to-child transmission (from an infected woman to her unborn child) and through blood transfusion and organ transplants [6-8].

Infection with *T. gondii* has severe consequences in immune compromised hosts such as pregnant women, HIV patients and patients receiving chemotherapy or immunosuppressive drugs [4, 5, 9]. The prevalence of toxoplasmosis among pregnant women showed significant variation between continents and countries and ranges from 9 - 92.5% [6, 8, 9]. In Cameroon, the prevalence ranges from 48.5 - 70% [5, 10]. This variation depends on social and cultural habits, geographic factors, individual's hygiene, route of transmission and the immune status [5, 10, 11]. The high prevalence in pregnant women

31 indicates a greater probability of congenital transmission with latent infection reactivated when immunity  
32 is suppressed [5, 12]. Reactivation of latent *T. gondii* infection causes severe and fatal neonatal  
33 complications such as stillbirth or abortion, anemia, petechiae due to thrombocytopenia, seizures,  
34 neurological defect (epilepsy), ocular disease (blindness, chorioretinitis, strabismus, retinoblastoma),  
35 microcephaly, brain damage (intracranial calcifications, hydrocephalus), mental retardation, cardiac and  
36 cerebral anomalies [8, 12, 13]. Congenital transmission of the infection during the first trimester is critical  
37 and causes severe clinical conditions in the fetus, whereas infections during the third trimester lead to  
38 rapid transmission [4, 14].  
39

40 Worldwide, about 36.7 million people are infected with HIV, but very little is known about the prevalence  
41 of HIV-1 co-infection with *T. gondii* parasites [15, 16]. Early HIV diagnosis and interventions among  
42 pregnant women have shown to decrease the likelihood of mother to child transmission [10, 17]. HIV  
43 prevalence is shown to increase among pregnant women as such screening all women during antenatal  
44 care is important [17, 18]. The prevalence of HIV among pregnant women ranges from 0.5-61.6% in other  
45 countries [11, 17, 19] and between 2.6 -22.1% within other towns in Cameroon [16, 20; 21]. With the  
46 advent of highly active antiretroviral therapy, the rate of mother to child transmission has greatly reduced  
47 to about 1.4-2.5% [18].  
48

49 *T. gondii* and HIV co-infections cause serious complications in pregnant women and pose a serious  
50 health threat [11]. Although screening practices of *T. gondii* and HIV during antenatal care are  
51 standardized in developed countries, it is somehow limited in developing countries where the burden of *T.*  
52 *gondii* infection among HIV infected pregnant women is greatly felt [20]. As such screening for *T. gondii*  
53 and HIV infections among pregnant women may be an important primary prevention strategy. Studies  
54 carried out elsewhere have shown co-infection rates between 12-40.8% [9, 12]. However, such data are  
55 dearth in many developing countries including Cameroon.  
56

57 This study is the first study to determine the prevalence of *T. gondii* and HIV co-infection among pregnant  
58 women in the Northwest region of Cameroon. It is hoped that the outcome of this study will enable  
59 policymakers to design effective strategies for controlling and preventing the disease which in turn will  
60 curb the maternal-fetal transmission rate alongside its associated complications. In addition, it will set a  
61 base for further studies to be carried out in this area.  
62

## 63 2. MATERIALS AND METHODS 64

### 65 Study site and design

66 This study was a hospital-based cross-sectional study conducted at the Bamenda Regional Hospital from  
67 May 2017 to December 2017. This hospital serves as a referral hospital for the entire Northwest region  
68 (NWR). The NWR is characterized by wet and hot climates which have been documented to favor *T.*  
69 *gondii* oocyst survival. Inhabitants in this region keep domestic animals like cats, sheep, dogs, goats,  
70 fowls that have shown to transmit the disease [4, 12]. Roasted meat (beef, pork, fish, and chicken) is a  
71 common delicacy eaten by most people on a daily basis and is a medium for ingesting infectious  
72 parasites.  
73

### 74 Sample size determination and sampling technique

75 The minimum sample size was calculated based on Toxoplasma morbidity using the Lorenz formula

$$76 \quad N = \frac{(Z_{1-\alpha})^2 P(1-P)}{i^2}$$

77 Where,  $Z_{1-\alpha}$  = the normal distribution value = 1.96

78  $P$  = Relative prevalence of HIV in the region = 54.5% [5]

79  $i$  = precision (sampling error) = 0.05

80 The minimum sample size (N) was calculated to be 382.

81 **Data collection**

82 A structured closed-ended questionnaire was used to obtain information on socio-demographic and  
83 obstetric data.

84 **Sample collection and processing**

85 A total of 2ml venous blood was collected using labeled test Ethylene diamine tetra acetic (EDTA) tubes  
86 by the hospital laboratory technician and centrifuged to obtain plasma. Diagnosis of toxoplasmosis was  
87 done using the OnSite ToxolgG/IgM rapid test (CTK Biotech Inc, USA) as per the manufacturer's  
88 procedure. This rapid test kit simultaneously detects both IgG and IgM anti-*Toxoplasma gondii* antibodies.  
89 Whereas HIV test was done using the Alere Determine™ HIV-1/2 test kit (Alere, Japan) and confirmatory  
90 test for those that were positive was done using OraQuick HIV 1/2 Rapid Antibody Test (for OraSure  
91 Technologies, Thailand) as described in the manufacturer's procedure.

92 **Data analysis**

93 The data were analyzed using the SPSS statistical software package version 23. Chi-square test was  
94 used for comparison between categorical variables through cross-tabulations. P-values of < 0.05 were  
95 considered statistically significant.

96  
97

98 **3. RESULTS AND DISCUSSION**

99

100 **3.1 RESULTS**

101 A total of 683 pregnant women were approached and, 650 provided consent for the study. Of these 606  
102 women who had recorded HIV status were considered for the study. The age range was 14-45 years with  
103 a mean (SD) of 27.3 (5.3) years. Of the 606 participants, the age group 21-30years 397 (65.5%) were the  
104 most represented, 362 (59.7%) participants were married and 301(49.7%) participants had attained  
105 secondary education. A greater number of them were multigravidae 381 (62.9%) and were in their third  
106 trimester of pregnancy 350(57.8%) (Table 1).

107  
108  
109

**Table 1: General characteristic of the study participants**

Demographic characteristics	Number (%)
<b>Age group in Years</b>	
<21	53(8.7)
21-30	397(65.5)
>30	156(25.7)
<b>Marital status</b>	
Single	164(27.1)
Concubine	58(9.6)
Married	362(59.7)
Widow	22(3.6)
<b>Level Educational</b>	
None	17(2.8)
Primary	107(17.7)
Secondary	301(49.7)
Tertiary	181(29.9)
<b>Gestational age classification</b>	
First (<14weeks)	106(17.5)
Second (14-28weeks)	150(24.8)
Third (>28weeks)	350(57.8)
<b>Gravidity (number of pregnancies)</b>	
Primigravidae (1)	199(32.8)
Multigravidae( 2-4)	381(62.9)
Grandmultigravidae (>4)	26(4.3)

110

112 **Prevalence of HIV-1**

113 The overall prevalence of HIV-1 amongst the participants was 70 (11.6%). The age group >35 years had  
 114 the highest HIV-1 prevalence (18.6%), while women <21 years had the lowest prevalence (5.7%). This  
 115 difference was statistically significant ( $p = 0.001$ ). The youngest seropositive pregnant woman was aged  
 116 17 years and the oldest was 42 years of age. HIV prevalence in pregnant women was relatively high  
 117 among married women 9(15.5%) and among women who had attended primary schools though the  
 118 difference was not significant ( $p = 0.45$ ). Furthermore, the prevalence of HIV-1 was significantly high ( $P =$   
 119  $0.02$ ) among women who started antenatal care at first trimester 20(18.9) and insignificantly high ( $P =$   
 120  $0.74$ ) among grand multigravidae 6(23.1) women (Table 2).

121

122

123 **Table 2: Univariate analysis of HIV prevalence according to socio-demographic and obstetrical**  
 124 **characteristics**

Demographic characteristics	Number (%)	HIV neg (%)	HIV pos (%)	OR (95% CI)	P value
<b>Age group in Years</b>					
<21	53(8.7)	50(94.3)	3(5.7)	0.22 (1.38-3.54)	0.001
21-30	397(65.5)	359(90.4)	38(9.6)		
>30	156(25.7)	127(81.4)	29(18.6)		
<b>Marital status</b>					
Single	164(27.1)	143(87.2)	21(12.8)	0.92 (0.6.3-1.34)	0.65
Concubine	58(9.6)	324(89.5)	38(10.5)		
Married	362(59.7)	49(84.5)	9(15.5)		
Widow	22(3.6)	20(90.9)	2(9.1)		
<b>Level Educational</b>					
None	17(2.8)	15(88.2)	2(11.8)	0.86 (0.62-1.23)	0.45
Primary	107(17.7)	93(86.9)	14(13.1)		
Secondary	301(49.7)	267(88.7)	34(11.3)		
Tertiary	181(29.9)	161(89.0)	20(11.0)		
<b>Gestational age classification</b>					
First (<14weeks)	106(17.5)	86(81.1)	20(18.9)	0.69 (0.51-0.97)	0.021
Second (14-28weeks)	150(24.8)	132(88.0)	18(12.0)		
Third (>28weeks)	350(57.8)	318(90.9)	32(9.1)		
<b>Gravidity (number of pregnancies)</b>					
Primi gravidae (1)	199(32.8)	175(87.9)	24(12.1)	1.09 (0.65-1.85)	0.74
Multi gravidae (2-5)	381(62.9)	341(89.5)	40(10.5)		
Grand multigravidae (>5)	26(4.3)	20(76.9)	6(23.1)		

125 **OR: odds ratio**

126

127

128 **Prevalence of *T. gondii***

129 Considering women with either anti-Toxoplasma IgG or anti-Toxoplasma IgM or both anti-Toxoplasma  
 130 IgG and IgM as positive for Toxoplasma infection, 139(22.9%) women presented with toxoplasmosis. Of  
 131 the 606 participants, 135 (22.3%) were found seropositive for anti-Toxoplasma IgG antibodies, while  
 132 11(1.8%) had anti-Toxoplasma IgM. This difference was statistically significant ( $p=0.00$ ). Seven (5.2%) of  
 133 the women tested positive for both IgG and IgM anti-Toxoplasma. Univariate analyses of demographic  
 134 and obstetrical characteristics showed no significant difference. However, the prevalence was highest  
 135 among age group <21years (24.5%;  $P = 0.37$ ), married women (25.9%;  $P = 0.46$ ), women who had

136 attained tertiary level of education (26.0%;  $P = 0.16$ ), 1<sup>st</sup> trimester women (29.2%;  $P = 0.65$ ), and  
 137 primigravidae women (28.1%;  $P = 0.07$ ) (Table 3)  
 138  
 139  
 140  
 141

142 **Table 3: Univariate analyses of demographic and obstetrical characteristics of *T. gondii***  
 143 **antibodies**

characteristics	<i>T. gondii</i> negative	<i>T. gondii</i> positive	Crude odds ratio	95% CI	P value
<b>Age group (Year)</b>					
<21	40(75.5)	13(24.5)	0.83	0.56-1.25	0.37
21-30	303(76.3)	94(23.7)			
>30	124(79.5)	32(20.5)			
<b>Marital status</b>					
Single	135(82.3)	29(17.7)	1.14	0.81-1.59	0.46
Married	271(74.9)	91(25.1)			
Concubine	43(74.1)	15(25.9)			
Widow	18(81.8)	4(18.2)			
<b>Level Educational</b>					
None	14(82.4)	3(17.6)	1.24	0.91-1.70	0.16
Primary	89(83.2)	18(23.6)			
Secondary	230(76.4)	71(23.6)			
Tertiary	134(74.0)	47(26.0)			
<b>Gestational age classification</b>					
First (<14weeks)	75(70.8)	31(29.2)	0.94	0.69-1.26	0.65
Second (14-28weeks)	112(74.7)	38(25.3)			
Third (>28weeks)	280(80.0)	70(20.0)			
<b>Gravidity</b>					
Primigravidae (1)	143(71.9)	56(28.1)	0.63	0.37-1.04	0.07
Muiltigravidae( 2-5)	301(79.0)	80(21.0)			
Grand muiltigravidae (>5)	23(88.5)	3(11.5)			

144 ***T. gondii* and HIV-1 and co-infection**

145 Of the 606 women, 31(5.1%) were positive for both HIV and *T. gondii*. Co-infection rate was high among  
 146 women of the age group 21-35 years (5.5%), single women 8(17.7%), women who never went to school  
 147 (5.9%), women who started antenatal cars at a gestational age of < 14 weeks (8.7%) and women with  
 148 more than 5 pregnancies (7.7%). This differences were however not significant  $p > 0.05$  (Table 4).  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161

162 **Table 4: univariate analyses of socio-demographic and obstetrical data of HIV and *T. gondii* co-**  
 163 **infection**

Demographic characteristics	Number (%)	Co-infection	P value
Age group (Year)			

<21	53(8.7)	1(1.9)	0.53
21-30	397(65.5)	22(5.5)	
>30	156(25.7)	8(5.1)	
<b>Marital status</b>			
Single	164(27.1)	8(17.7)	0.30
Concubine	362(59.7)	16(4.4)	
Married	58(9.6)	6(10.3)	
Widow	22(3.6)	1(4.5)	
<b>Level Educational</b>			
None	17(2.8)	1(5.9)	0.91
Primary	107(17.7)	4(3.7)	
Secondary	301(49.7)	16(5.3)	
Tertiary	181(29.9)	10(5.5)	
<b>Gestational age classification</b>			
First (<14weeks)	106(17.5)	9(8.5)	0.07
Second (14-28weeks)	150(24.8)	10(6.7)	
Third (>28weeks)	350(57.8)	12(3.4)	
<b>Gravidity</b>			
Primigravidae (1)	199(32.8)	10(5.0)	0.83
Multigravidae( 2-5)	381(62.9)	19(5.0)	
Grandmultigravidae (>5)	26(4.3)	2(7.7)	

164

165

### 3.2 DISCUSSION

166 This study is one of the few studies carried out in Cameroon to explore the risk factors associated with *T.*  
167 *gondii* and the seroprevalence of *T. gondii* and HIV co-infection among pregnant women in Bamenda  
168 Health District.

169

170 Despite the low HIV prevalence (4.3%) in Cameroon in 2016 [22], the prevalence of HIV (11.6%) among  
171 pregnant women was high compared to the 0.5-10.3% range reported in other countries of the world [14,  
172 17, 23] and from other towns in Cameroon [20, 21]. However, it was quite low compared to the 61.6%  
173 reported by Simpore *et al.*, [11] in a study carried out in Burkina Faso.

174

175 There was no statistical significance between marriage, level of education, gravidity and HIV-1 infection  
176 ( $p < 0.05$ ). However, the risk of contracting the disease was 78%, 8%, 14%, and 31% less likely to occur  
177 in women of the age group >30years, widows, those who attain secondary school, and women who  
178 started ANC at third trimester respectively, while the risk was 9% more likely to occur in grand  
179 multigravidae women. In this study, HIV-1 prevalence was highest among the age group >30 years  
180 contrary to the previous studies [12, 23] which state that HIV-1 prevalence was high in the 21–25years  
181 age range. Similar results have been reported in a different town in Cameroon [16]. This is most likely due  
182 to progressive increase duration of exposure to sexual activity in this age group compared to a lower age  
183 group. In addition, the majority of the women, in the >30years age range were multigravida or grand  
184 multigravida indicating that they have been exposed more to unprotected sexual intercourse which is a  
185 risk factor for HIV infection.

186 As reported in other studies [19, 23, 24] married women had a high HIV prevalence (15.5%). However, is  
187 contrary to another study from a different town in Cameroon where single women were more infected  
188 [16]. It has been reported that susceptibility and vulnerability to HIV/AIDS are attributed to marital and  
189 family status [25]. This high HIV prevalence in the group of women is associated with the fact that married  
190 women usually have unprotected sex and in addition, it was difficult to assess information on multiple  
191 partners in these women although extramarital affairs are common in the said setting.

192 Data from this study showed that woman who had attained primary education had the highest HIV  
193 prevalence (13.1%) followed by those who did not go to school (11.8%). This may be attributed to lack of  
194 adequate information on the mode of transmission and prevention of HIV and other STDs. This result is  
195 similar to studies by [17, 23] and contrary to other studies where women with tertiary education had a  
196 higher HIV seroprevalence [19, 26].

197 Prevalence of HIV in this study was insignificantly high among women who were multigravida similar to  
198 report by Nayak *et al.*, [23] and contrary to the previous study done by Patil *et al.*, [25] where HIV was

199 common among primigravida. The high prevalence is associated with increased risk of unprotected  
200 sexual intercourse in this group of women

201  
202 The seroprevalence of *T. gondii* infection was 22.9% while seroprevalence for anti-Toxoplasma IgG and  
203 IgM, antibodies were 22.3% and 1.8% respectively. The risk of contracting *Toxoplasma* was 93%, 16%,  
204 and 37% less likely to occur in the age group >30years, women who started ANC at second trimester and  
205 grand multigravidae women respectively, while the risk was 14% and 24% more likely to occur in women  
206 in a concubine relationship and women who had attained tertiary education respectively. The  
207 seroprevalence of *T. gondii* infection in this study was found to be lower than the 30-90% range reported  
208 in different countries [6, 8, 12] and was higher compared to the 5.9- 18.5% range in other studies [4, 27,  
209 28]. In Cameroon, previous studies have reported a range of 54.4-77.1% [5, 10, 29]. The differences seen  
210 with other studies can be attributed to environmental or climatic conditions favoring the transmission and  
211 infectivity of *T. gondii* oocysts, diagnostic methods, living styles, standards of the people, sampled  
212 populations, cultural characteristics, personal hygienic practice, feeding habits and genetic background  
213 [6, 10, 30]. This decrease in prevalence can be as a result of the awareness that is been created from the  
214 result of previous studies.

215  
216 Detection of both IgG and IgM simultaneously helps to establish the chronological status of *T. gondii* [31].  
217 Toxoplasma IgG antibodies indicate a chronic infection while Toxoplasma IgM antibodies indicate an  
218 acute infection [8, 12]. The high prevalence of Toxoplasma IgG compared to Toxoplasma IgM antibodies  
219 seen in this study have been reported elsewhere [7, 30, 32]. The low IgM (1.8%) antibodies indicate a low  
220 level of acute Toxoplasma infection. It has been reported that acute Toxoplasma infection is associated  
221 with a higher risk of maternal-fetal transmission [7, 33]. Thus the early diagnosis of Toxoplasmosis in  
222 pregnant mothers is of great importance for early initiation of measures and therapy that reduce the risk  
223 of transmission and possible consequence on the newborn. On the other hand, other studies did not  
224 report the presence of *T. gondii*-specific IgM [8, 11, 12]. However, it has been reported that IgM antibody  
225 is usually detected within the first two weeks of infection and reduces to negligible levels within 6 months  
226 after exposure [11, 12]. This accounts for the low prevalence seen in this study as most women (62.2%)  
227 came to ANC at a gestational age of >24 weeks. Nevertheless, other studies have shown that the  
228 presence of IgM may not be an acute infection since IgM can persist for prolonged times after infection  
229 [28, 29]. Thus further research in this area is required to ascertain this fact.

230  
231 Other studies have reported that the risk of contracting *T. gondii* infection increases with age unlike the  
232 case in this study [34, 35]. Though age was not a risk factor to the *T. gondii* infection, younger women  
233 <21 years were more infected compared to older women. This result contradicts studies by [4, 6, 28] that  
234 identify age group > 21 years as a risk factor. In addition, the result is similar to studies by Njunda *et al.*,  
235 [10] and Shimelis *et al.*, [36] which state that seroprevalence of *T. gondii* does not depend on age.  
236 Nevertheless, another study in Cameroon indicates that women aged between 31-35years had a higher  
237 prevalence [10]. The variation in age classification of the different studies can also account for the  
238 variation of the results seen in the different studies. The high prevalence in younger women can be  
239 attributed to their lifestyle. It has been reported that younger people are more exposed to activities like  
240 grilled meat or fish which might be undercooked as well as raw food like fruits and salad which may be  
241 contaminated with the parasites hence increased risks of infection [12, 13].

242  
243 In this study no significant association was found between the seroprevalence of toxoplasmosis and  
244 educational status as opposed to a study by da Silva *et al.*, [1] who reported low education or illiteracy as  
245 a risk factor. A similar finding was recorded by Walle *et al.*, [31]. On the contrary women with tertiary  
246 school education which suggests a better understanding of hygiene principles had the highest prevalence  
247 of toxoplasmosis. The high prevalence in this group can be attributed with higher socioeconomic  
248 standards such as eating of raw vegetables, fruit and roasted meats which have been identified sources  
249 of disease transmission.

250 The degree of severity of the disease depends on the gestational age as severe fetal affection occurred  
251 with early gestational age infection [32]. Gestational age did not show any significant association as also  
252 reported by Frimpong *et al.*, [4] in another study. Contrary to this study, data presented by Shao *et al.*,  
253 [13] showed that gestational age was a significant risk factor. The highest seroprevalence of Toxoplasma  
254 antibodies (29.2%) was found in pregnant women at the first trimester is similar to the result of Alsammani  
255 [35] contrary to second and third semesters [4, 24].

256 Despite the non-statistical significant association contrary to another study [6], data from this study  
257 showed that the risk of toxoplasmosis decreases with increase in gravidity. Primigravidae recorded the  
258 highest prevalence of 56(28.1%). This result is contrary to other studies by Awoke *et al.*, [28] and Negero  
259 *et al.*, [6] which state that *T. gondii* is more likely to occur in multigravidae. The likely reason for this result  
260 is that the test for *T. gondii* has been encouraged for more than 5 years in this setting. As such women  
261 with multiple pregnancies are were knowledgeable with the method of prevention than primigravidae  
262 women. Secondly, previously infected women must have been treated prior to the present pregnancy.  
263  
264

265 In this study, no significant difference was seen between seropositivity of *T. gondii* in HIV positive  
266 31(44.3%) and negative 108(20.1%) women similar to studies in other countries [4, 14, 24]. The high  
267 prevalence in this group is as a result of decreased immunity which leads to reactivation of latent  
268 infection/tissue toxoplasmosis in HIV positive women [9, 30]. The reason for the non-significance in this  
269 study can be as a result of the use of antiretroviral therapy (ART). ART suppresses HIV viral replication  
270 and increased CD4<sup>+</sup> T-cell counts, therefore, preventing the development of opportunistic infections. In  
271 addition, since 2012, Bamenda health district in Cameroon has been implementing the test and treat  
272 method (option B+) where all HIV pregnant or breastfeeding mothers are placed on ART irrespective of their  
273 CD4<sup>+</sup> T cell counts or WHO clinical stage [18]. On the other hand studies by Siteo *et al.*, [37] and Walle *et*  
274 *al.*, [31] showed a significant difference in the prevalence rate between HIV positive and negative women.  
275

276 In this study we recorded a prevalence of 5.1% co-infection rates lower than the 12- 25% range in other  
277 studies [5, 12] but higher compared to the 2.1% reported by Fernandes *et al.*, [14]. HIV and *T. gondii* co-  
278 infection rate are common in pregnant women because both pregnancy and HIV weakens the immune  
279 system that favors *T. gondii* and other opportunistic infection to occur [11, 12]. Furthermore, it is more  
280 likely that these women with co-infection were recently diagnosed with HIV and were not on treatment or  
281 were newly initiated on treatment. In addition, HIV-1 and *T. gondii* co-infection could be attributed to  
282 common social lifestyle or associated risk factors common to both infections, such as exposure to sexual  
283 contacts, consumption of undercooked meat or roasted meat and raw vegetable.  
284

#### 284 Limitation

285 The present study has certain limitations that need to be taken into account. No CD4<sup>+</sup> T cells count was  
286 measured, History on ART was not taken into consideration, or the year of HIV diagnosis was not known  
287 by most women.  
288  
289

#### 290 4. CONCLUSIONS

291 This study demonstrates that the prevalence of *T. gondii* infection among pregnant women is decreasing.  
292 The high prevalence of *T. gondii* and HIV co-infection among pregnant women indicates a greater  
293 probability of congenital transmission of *T. gondii*.  
294

#### 295 RECOMMENDATION

296 The high prevalence of *T. gondii* and HIV-1 co-infection indicate the need to intensify the education of the  
297 associated risk factors of both *T. gondii* and HIV-1 infections and methods of prevention. This will reduce  
298 the risk of mother to child transmission and thus prevent the consequences of toxoplasmosis and HIV in  
299 children. In addition, serological screening for *T. gondii* infection should be considered as part of an  
300 antenatal investigation during ANC follow-up.  
301



302 **COMPETING INTERESTS**

303

304 We have no competing interest

305

306 **ETHICAL CONSIDERATIONS**

307 Ethical clearance and administrative authorization were obtained from the ethical review board  
308 of the delegation of Public Health Bamenda and Bamenda Regional Hospital review board.

309 **CONSENT**

310 Each subject gave their informed and written consents before sample collection. Participation in  
311 the study was on a voluntary basis and study participants were free to withdraw from the study  
312 before and after collection of blood samples without losing any of the benefits they were  
313 supposed to obtain from the hospital.

314

315

316 **REFERENCES**

- 317 1. da Silva MG, Vinaud MC, de Castro AM. Prevalence of toxoplasmosis in pregnant women and  
318 vertical transmission of *Toxoplasma gondii* in patients from basic units of health from Gurupi,  
319 Tocantins, Brazil, from 2012 to 2014. *PLoS One*. 2015 Nov 11;10(11):e0141700.
- 320 2. Nguetack HL, Gwet H, Desmonde S, Oukem-Boyer OO, Nkenfou C, Téjiokem M, et al.  
321 Estimating mother-to-child HIV transmission rates in Cameroon in 2011: a computer simulation  
322 approach. *BMC infectious diseases*. 2015 Dec;16(1):11.
- 323 3. Dawit G, Shishay K. Epidemiology, public health impact and control methods of the most  
324 neglected parasite diseases in Ethiopia: a review. *World J Med Sci*. 2014;10:94-102.
- 325 4. Frimpong C, Makasa M, Sitali L, Michelo C. Seroprevalence and determinants of toxoplasmosis  
326 in pregnant women attending antenatal clinic at the university teaching hospital, Lusaka, Zambia.  
327 *BMC infectious diseases*. 2017 Dec;17(1):10.
- 328 5. Wam EC, Sama LF, Ali IM, Ebile WA, Aghangu LA, Tume CB. Seroprevalence of *Toxoplasma*  
329 *gondii* IgG and IgM antibodies and associated risk factors in women of child-bearing age in  
330 Njinikom, NW Cameroon. *BMC research notes*. 2016 Dec;9(1):406.
- 331 6. Negero J, Yohannes M, Woldemichael K, Tegegne D. Seroprevalence and potential risk factors  
332 of *T. gondii* infection in pregnant women attending antenatal care at Bonga Hospital,  
333 Southwestern Ethiopia. *International Journal of Infectious Diseases*. 2017 Apr 1;57:44-9.
- 334 7. Yohanes T, Zerdo Z, Chufamo N. Seroprevalence and predictors of hepatitis B virus infection  
335 among pregnant women attending routine antenatal care in Arba Minch Hospital, South Ethiopia.  
336 *Hepatitis research and treatment*. 2016;2016.
- 337 8. Paul E, Kiwelu I, Mmbaga B, Nazareth R, Sabuni E, Maro A, et al. *Toxoplasma gondii*  
338 seroprevalence among pregnant women attending antenatal clinic in Northern Tanzania. *Tropical*  
339 *medicine and health*. 2018 Dec;46(1):39.
- 340 9. Nazari N, Bozorgomid A, Janbakhsh A, Bashiri F. *Toxoplasma gondii* and human  
341 immunodeficiency virus co-infection in western Iran: A cross-sectional study. *Asian Pacific*  
342 *Journal of Tropical Medicine*. 2018 Jan 1;11(1):58.
- 343 10. Njunda AL, Assob JC, Nsagha DS, Kamga HL, Nde PF, Yugah VC. Seroprevalence of  
344 *Toxoplasma gondii* infection among pregnant women in Cameroon. *Journal of public health in*  
345 *Africa*. 2011 Sep 5;2(2).
- 346 11. Simpore J, Savadogo A, Ilboudo D, Nadambega MC, Esposito M, Yara J, et al. *Toxoplasma*  
347 *gondii*, HCV, and HBV seroprevalence and co-infection among HIV-positive and-negative  
348 pregnant women in Burkina Faso. *Journal of medical virology*. 2006 Jun;78(6):730-3.
- 349 12. Okwuzu JO, Odunukwe NN, Ezechi OC, Gbajabiamila TA, Musa AZ, Ezeobi PM, et al.  
350 *Toxoplasma gondii* infection in HIV/AIDS: prevalence and risk factors. *African Journal of Clinical*  
351 *and Experimental Microbiology*. 2014;15(2):97-102.
- 352 13. Shao ER, Ndazana SG, Chacha W, Masenga G, Tolbert S, Moshia D, et al. Sero-Prevalence and  
353 Factors Associated with *Toxoplasma Gondii* Infection among Pregnant Women Attending

354 Antenatal Care in the Referral Hospital in Tanzania: Cross Sectional Study iMedPub Journals.  
355 Annals of Clinical and Laboratory Research. 2015;3(2):17.

356 14. Fernandes MA, Batista GI, Carlos JD, Gomes IM, Azevedo KM, Setúbal S, Oliveira SA, et al.  
357 Toxoplasma gondii antibody profile in HIV-1-infected and uninfected pregnant women and the  
358 impact on congenital toxoplasmosis diagnosis in Rio de Janeiro, Brazil. Brazilian Journal of  
359 Infectious Diseases. 2012 Apr;16(2):170-174.

360 15. Wang ZD, Wang SC, Liu HH, Ma HY, Li ZY, Wei F, et al. Prevalence and burden of Toxoplasma  
361 gondii infection in HIV-infected people: a systematic review and meta-analysis. The Lancet HIV.  
362 2017 Apr 1;4(4):e177-88.

363 16. de Dieu Anoubissi J, Gabriel EL, Nde CK, Fokam J, Tseuko DG, Messeh A, Moussa Y, Nkenfou  
364 CN, Bonono L, Billong SC, Nfetam JB. Factors Associated with Risk Of HIV-Infection Among  
365 Pregnant Women in Cameroon: Evidence from the 2016 National Sentinel Surveillance Survey of  
366 HIV and syphilis. BioRxiv. 2018 Jan 1:482901.

367 17. Yang S, Yang C, Liao Q, Zhai W, Yu G, Xiao L, et al. Analysis of HIV prevalence among  
368 pregnant women in Liangshan Prefecture, China, from 2009 to 2015. PloS one. 2017 Sep  
369 7;12(9):e0183418.

370 18. Kalua T, Barr BA, Van Oosterhout JJ, Mbori-Ngacha D, Schouten EJ, Gupta S, et al. Lessons  
371 learned from option B+ in the evolution toward "test and start" from Malawi, Cameroon, and the  
372 United Republic of Tanzania. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017  
373 May 1;75: S43-50.

374 19. Kiptoo M, Mpoke S, Mueke J, Okoth F, Songok E. Survey on prevalence and risk factors on HIV-  
375 1 among pregnant women in North-Rift, Kenya: a hospital-based cross-sectional study conducted  
376 between 2005 and 2006. BMC international health and human rights. 2009 Dec;9(1):10.

377 20. Dionne-Odom J, Mbah R, Rembert NJ, Tancho S, Halle-Ekane GE, Enah C, et al. Hepatitis B,  
378 HIV, and syphilis seroprevalence in pregnant women and blood donors in Cameroon. Infectious  
379 diseases in obstetrics and gynecology. 2016;2016.

380 21. Sama CB, Fetei VF, Tindong M, Tanyi JT, Bihle NM, Angwafo III FF. Prevalence of maternal HIV  
381 infection and knowledge on mother-to-child transmission of HIV and its prevention among  
382 antenatal care attendees in a rural area in northwest Cameroon. PloS one. 2017 Feb  
383 15;12(2):e0172102.

384 22. Teto G, Tagny CT, Mbanya D, Fonsah JY, Fokam J, Nchindap E, et al. Gag P2/NC and pol  
385 genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02\_AG-and non-  
386 CRF02\_AG-infected patients in Yaounde, Cameroon. Scientific reports. 2017 Oct 26;7(1):14136.

387 23. Nayak AK, Jain MK, Dhivya S, Hota S. A study on the prevalence of HIV infection among  
388 pregnant women attending antenatal clinic in a tertiary care hospital, Cuttack, India. International  
389 Journal Of Community Medicine And Public Health. 2017 Apr 24;4(5):1504-9.

390 24. Gelaye W, Kebede T, Hailu A. High prevalence of anti-toxoplasma antibodies and absence of  
391 Toxoplasma gondii infection risk factors among pregnant women attending routine antenatal care  
392 in two Hospitals of Addis Ababa, Ethiopia. International Journal of Infectious Diseases. 2015 May  
393 1;34:41-5.

394 25. Patil VM, Moray AP, Patil SP. Ten years trend of HIV seroprevalence among Indian Pregnant  
395 women attending antenatal clinic at a tertiary hospital in Dhule, Maharashtra. India. IJRCOG.  
396 2016;5(5):1514-9.

397 26. Smith J, Nalagoda F, Wawer MJ, Serwadda D, Sewankambo N, Konde-Lule J, et al. Education  
398 attainment as a predictor of HIV risk in rural Uganda: results from a population-based study.  
399 International journal of STD & AIDS. 1999 Jul 1;10(7):452-9.

400 27. Cong W, Dong XY, Meng QF, Zhou N, Wang XY, Huang SY, et al. Toxoplasma gondii infection in  
401 pregnant women: a seroprevalence and case-control study in Eastern China. BioMed research  
402 international. 2015;2015.

403 28. Awoke K, Nibret E, Munshea A. Sero-prevalence and associated risk factors of Toxoplasma  
404 gondii infection among pregnant women attending antenatal care at Felege Hiwot Referral  
405 Hospital, northwest Ethiopia. Asian Pacific journal of tropical medicine. 2015 Jul 1;8(7):549-54.

406 29. Ndumbe PM, Andela A, Nkemnkeng-Asong J, Watonsi E, Nyambi P. Prevalence of infections  
407 affecting the child among pregnant women in Yaounde, Cameroon. Medical microbiology and  
408 immunology. 1992 Jul 1;181(3):127-30.

409 30. Yusuf AM, Yahaya S, Azeez-Akande O. Seroprevalence and risk factors of Toxoplasma gondii  
410 infection (toxoplasmosis) among HIV seropositive pregnant women in a tertiary healthcare centre,  
411 Kano, Northern Nigeria. J. Med. Med. Sci. 2016 Feb;7:001-5.

- 412 31. Walle F, Kebede N, Tsegaye A, Kassa T. Seroprevalence and risk factors for Toxoplasmosis in  
413 HIV infected and non-infected individuals in Bahir Dar, Northwest Ethiopia. *Parasites & vectors*.  
414 2013 Dec;6(1):15.
- 415 32. Kamal AM, Ahmed AK, Abdellatif MZ, Tawfik M, Hassan EE. Seropositivity of toxoplasmosis in  
416 pregnant women by ELISA at Minia University Hospital, Egypt. *The Korean journal of*  
417 *parasitology*. 2015 Oct;53(5):605.
- 418 33. Chaudhry SA, Gad N, Koren G. Toxoplasmosis and pregnancy. *Canadian Family Physician*. 2014  
419 Apr 1;60(4):334-6.
- 420 34. Elsheikha HM, Aboul-Dahab MA, Abdel AM, El-Sherbini ET. Prevalence and risk factors of  
421 *Toxoplasma gondii* antibodies in asymptomatic Egyptian blood donors. *Journal of the Egyptian*  
422 *Society of Parasitology*. 2009 Apr;39(1 Suppl):351-61.
- 423 35. Alsammani MA. Sero-epidemiology and risk factors for *Toxoplasma gondii* among pregnant  
424 women in Arab and African countries. *Journal of Parasitic Diseases*. 2016 Sep 1;40(3):569-79.
- 425 36. Shimelis T, Tebeje M, Tadesse E, Tegbaru B, Terefe A. Seroprevalence of latent *Toxoplasma*  
426 *gondii* infection among HIV-infected and HIV-uninfected people in Addis Ababa, Ethiopia: A  
427 comparative cross-sectional study. *BMC Research Notes*. 2009 Dec;2(1):213.
- 428 37. Siteo SP, Rafael B, Meireles LR, Andrade Jr HF, Thompson R. Preliminary report of HIV and  
429 *Toxoplasma gondii* occurrence in pregnant women from Mozambique. *Revista do Instituto de*  
430 *Medicina Tropical de São Paulo*. 2010 Dec;52(6):291-5.

431  
432  
433

#### 434 **DEFINITIONS, ACRONYMS, ABBREVIATIONS**

435 ART: antiretroviral therapy, AOR: adjusted odds ratio, CI: confidence interval, HIV: human  
436 immunodeficiency virus, *T: Toxoplasma*

437

438